Sarcoma patients share their experience on a second chemo round

NCT ID NCT06050434

Terminated Knowledge-focused Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to track how soft tissue sarcoma patients feel—symptoms, side effects, and quality of life—when they receive trabectedin chemotherapy again after a break. Only 7 patients were enrolled before the study was stopped early. The goal was to gather real-world patient feedback to guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trabectedin (chemotherapy)
What this could lead to: If successful, this study could help doctors understand how sarcoma patients feel during a second round of trabectedin, potentially improving care decisions.
What could go wrong: This was a small, terminated study with only 7 participants, so results may be limited and not apply to all patients. It focuses on patient reports, not on proving the drug works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA

Contacts and locations

Locations

Frankfurt Universitätsklinikum

Frankfurt am Main, Germany
HELIOS KLinikum Bad Saarow

Bad Saarow, Germany
HELIOS Klinikum Berlin Buch

Berlin, Germany
Uniklinikum Leipzig

Leipzig, Germany
Universitätsklinikum Tübingen

Tübingen, Germany
Universitätsmedizin Greifswald

Greifswald, Germany
Universitätsmedizin Göttingen

Göttingen, Germany
Universitätsmedizin Mainz

Mainz, Germany
Westfälische Wilhelms-Universität Münster

Münster, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.